Team Nordics hasn't added a story.
About the 2019 Country 2 Country 4 Cancer Ride
After the great success of the last three editions of the
European Country 2 Country 4 Cancer ride,
Bristol-Myers Squibb
employees from across Europe will again ride over 3’600 km from
Germany to the UK. Along the way, they will ride through
Switzerland, Italy, France and Spain, all to raise funds for cancer
research and organisations that support cancer patients in Europe.
Each of the organisations benefiting are members of the Union for
International Cancer Control.
In this 4th edition of the ride starting on 9 September 2019 and
lasting 18 days, over 80 European
Bristol-Myers Squibb
team members will be riding in 6 different country teams and
each group will be performing a leg of the ride averaging 720 km in
3 days.
Raising funds for SMILfonden
Cancer is among the leading causes of death worldwide. Each
year, there are 18.1
million new cases and 9.6 million
cancer-related deaths worldwide, and these numbers are growing.
This is why the Team Nordics – riding 720km across France and Spain –
has chosen to support
SMILfonden
in its mission to support cancer patients.
Encourage your colleagues, families and friends to donate, as cancer
affects us all.
Who are the riders
The participants are novice riders, who have committed
themselves to 5 months of intensive training to complete their
portion of the ride. Some are cancer survivors, others have
witnessed the devastating impact of cancer on friends and family.
Their kilometers will help raise funds to fight against cancer by
supporting SMILfonden, a member of the Union for
International Cancer Control.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines that
help patients prevail over serious diseases.
About the Union for International Cancer Control
The
Union for International Cancer Control
(UICC) is dedicated to taking the lead in convening,
capacity building and advocacy initiatives that unite the cancer
community to reduce the global cancer burden, promote greater equity,
and integrate cancer control into the world health and development agenda.